Cosmos Health evaluates asset monetization and share repurchases as it projects USD 12 million in NOOR Collagen revenue

Reuters
Mar 20
<a href="https://laohu8.com/S/COSM">Cosmos Health</a> evaluates asset monetization and share repurchases as it projects USD 12 million in NOOR Collagen revenue
  • Cosmos Health said it will issue updated operational, strategic and financial guidance after releasing its fourth quarter and full-year 2025 results.
  • Sky Premium Life products sold in the U.S. are expected to generate gross margins of about 75%.
  • NOOR Collagen is projected to generate more than USD 12 million in annualized revenue.
  • The company said it entered an LOI to acquire a pharmacy distribution network generating about USD 11.5 million in annual gross revenue.
  • Cosmos Health said it holds non-core assets with an estimated fair market value exceeding USD 18 million, including real estate valued at about USD 15 million.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cosmos Health Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603191245OMX_____CNEWS_EN_GNW9675399_en) on March 19, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10